HLA-C and neoplasm: ICIs consist in a growing number of monoclonal antibodies (MAs) that target checkpoint molecules in T-cells or their ligands in antigen-presenting cells (APCs), tumor cells, and other cell types, which usually regulate the T-cell response to the antigen-major histocompatibility complex (MHC) on APCs.7 ICIs unbalance T-cell regulation by blocking the checkpoint molecules that normally inhibit T-cell activity directed against tumor cells or by activating in an agonist way the stimulation of one of the molecules that usually speed up T-cell-mediated tumor cell surveillance and destruction.7